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TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to 
mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry (IHC) for TP53 has 
been established as a proxy for the TP53 mutation status in other ovarian tumor types. We 
aimed to confirm the ability of TP53 IHC to predict TP53 mutation status in ovarian 
mucinous tumors and to evaluate the association of TP53 mutation status with survival 
among patients with MBOT and MOC. Tumor tissue from an initial cohort of 113 women 
with MBOT/MOC was stained with optimized IHC for TP53 using tissue microarrays (75.2%) 
or full sections (24.8%) and interpreted using established criteria as normal or abnormal 
(overexpression, complete absence, or cytoplasmic). Cases were considered concordant if 
abnormal IHC staining predicted deleterious TP53 mutations. Discordant tissue microarray 
cases were re-evaluated on full sections and interpretational criteria were refined. The 
initial cohort was expanded to a total of 165 MBOT and 424 MOC for the examination of the 
association of survival with TP53 mutation status, assessed either by TP53 IHC and/or 
sequencing. Initially, 82/113 (72.6%) cases were concordant using the established criteria. 
Refined criteria for overexpression to account for intratumoral heterogeneity and terminal 
differentiation improved concordance to 93.8% (106/113). In the expanded cohort, 19.4% 
(32/165) of MBOT showed evidence for TP53 mutation and this was associated with a 
higher risk of recurrence, disease-specific death and all-cause mortality (overall survival: 
HR=4.6, 95%CI 1.5-14.3, p=0.0087). Within MOC, 61.1% (259/424) harbored a TP53 
mutation, but this was not associated with survival (overall survival, p=0.77). TP53 IHC is an 
accurate proxy for TP53 mutation status with refined interpretation criteria accounting for 
intratumoral heterogeneity and terminal differentiation in ovarian mucinous tumors. TP53 





Ovarian mucinous tumors are uncommon neoplasms with an elusive cell of origin (1). They 
comprise a spectrum of entities, including mucinous cystadenoma/adenofibroma, mucinous 
borderline tumor (MBOT), and mucinous ovarian carcinoma (MOC). All these entities are 
often seen in a single ovarian mucinous tumor giving rise to morphological heterogeneity, 
and supporting a multi-step progression model to MOC where genomic loss of CDKN2A and 
KRAS mutations are initiating events (2, 3). We have recently shown that TP53 mutations 
and copy number aberrations are key drivers of progression from borderline precursors to 
MOC, given these genetic alterations are significantly enriched in carcinomas compared to 
benign precursors (4, 5). An early study reported TP53 overexpression in MBOT with 
microinvasion, microcarcinoma, and coexisting carcinoma (6). Anecdotal cases where a TP53 
mutated MBOT widely metastasized within a few years of diagnosis have been reported (7). 
 
While TP53 sequencing is not routinely clinically accessible, we have recently established 
that optimized TP53 immunohistochemistry (IHC) is a good proxy for TP53 mutation 
detection by sequencing in (tubo-) ovarian and endometrial carcinomas with approximately 
95% accuracy (8, 9). TP53 IHC, as an alternative to tumor sequencing, can be applied in a 
cost-effective and high-throughput manner for diagnostic purposes and in prognostic 
studies using tissue microarrays (TMA). However, we find that there are context dependent 
differences across tumor types: 5% of endometrial carcinomas show subclonal TP53 
patterns, which are defined by a combination of normal and abnormal TP53 IHC (9). The 
interpretation of TP53 IHC had to be adapted for TP53 mutation detection in squamous cell 
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carcinomas because of the phenomenon of terminal differentiation, in which terminally 
differentiated cells no longer express TP53, regardless of mutation status (10, 11).  
 
The primary objective of this study was to assess the correlation between TP53 IHC and 
TP53 mutation screening by sequencing in MOC and MBOT using established and refined 
criteria for TP53 IHC interpretation in ovarian mucinous tumors. A second aim was to 
evaluate the association of TP53 status and survival among patients with MOC and MBOT. 
 
 
Materials and Methods 
 
Cohort 
Our analysis included tissue from 647 ovarian mucinous tumors assembled from two 
cohorts of patients. 295 specimens were obtained from the previously described Genomic 
Analysis of Mucinous Tumors (GAMuT) cohort (5). The GAMuT cohort consists of cases 
diagnosed as ovarian mucinous tumors from Australia (Australian Ovarian Cancer Study 
(AOCS), Royal Women’s Hospital, Queensland Institute for Medical Research - Berghofer, 
The Hudson Institute of Medical Research, Garvan Institute of Medical Research and 
Westmead Hospital GynBiobank), the United States (Mayo Clinic, Rochester), Canada 
(Canadian Ovarian Experimental Unified Resource (COEUR) and OVCARE), and the United 
Kingdom (South England and Edinburgh). Sequencing data were available for 234 GAMuT 
cases and a subset (n=113) had corresponding tissue microarrays (TMA) and/or full sections 
available, which were used for the initial TP53 IHC - TP53 mutation concordance analysis. 
Sixty-one GAMuT cases had TP53 IHC without mutation data. An additional 352 specimens 
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were sourced from the Ovarian Tumor Tissue Analysis (OTTA) Consortium, which have been 
recently subjected to a biomarker-integrated review to exclude lower gastrointestinal tract 
metastases (12). Local pathology review with or without use of IHC was performed. These 
cases were represented on TMA by a median of two tissue cores and therefore were 
available for TP53 IHC but not DNA sequencing. The overall case flow is summarized in 
Supplementary Figure S1. All study sites received ethics board approval for tumor profiling 
(Supplementary Table S1). 
 
TP53 mutation sequencing 
TP53 mutation sequence data was obtained from previously performed analyses (3, 5) that 
included whole genome sequencing (N=5), whole exome sequencing (N=57), targeted 
mutation sequencing (N=152), and Sanger sequencing for exons 4-9 (N=20). A subset (N=41) 
was additionally validated by Sanger sequencing. Allele frequencies were determined taking 
into account estimated cellularity and loss of heterozygosity, and mutations were 
categorized by type (missense, inframe indel, truncating (stop-gain and frameshift), and 
splicing). Deleterious missense mutations were classified using public databases (13, 14). 
 
Immunohistochemistry 
TP53 IHC was performed on formalin-fixed and paraffin-embedded (FFPE) tissue sections of 
4 um thickness. The majority of staining was performed at the Department of Pathology and 
Laboratory Medicine, University of Calgary, Canada, including 80/113 (70.8%) cases from 
the initial GAMuT cohort, all quality control full sections, and all TMAs from the OTTA 
cohort. Cases were stained using a previously published protocol (9). After 30 minutes of 
heat-induced pre-treatment using the high pH retrieval buffer, the DAKO Omnis protocol 
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H30-10M-30 with the ready-to-use clone DO-7 (catalog # GA61661-2; DAKO) was utilized. 
From the remaining initial cohort, 24/113 cases were stained using full sections at the 
Department of Pathology, Peter MacCallum Cancer Centre, Australia, and 5 cases in TMAs 
were stained at the originating center, also using clone DO-7. For 4 cases, tissue was not 
available for analysis and therefore, the TP53 IHC status was retrieved from pathology 
reports issued for these cases. 
 
Interpretation was initially performed according to established criteria for ovarian and 
endometrial carcinomas (15). IHC and sequencing results were independently interpreted 
with evaluators of either component blinded to the other result. Abnormal (also variably 
referred to as mutation-type or aberrant) TP53 staining showed one of 3 patterns: 
overexpression (OE) with virtually all viable tumor cell nuclei showing strong nuclear 
staining; complete absence (CA; also referred to as “null pattern”) with no nuclear staining 
of tumor cells but with normal control staining in non-tumor stromal or immune cells 
providing an internal control; and cytoplasmic (CY) with unequivocal cytoplasmic staining 
and variable nuclear staining. By contrast, tumors with normal (also referred to as wild-type 
pattern) staining showed nuclear expression of variable intensity and cellular distribution. If 
no staining was seen in any cells (CA in tumor cells and no internal control), the sample was 
excluded from the study. 
 
Based on the observation of intratumoral heterogeneity (subclonal abnormal patterns) and 
terminal differentiation in ovarian mucinous tumors, the criteria were refined. In cases 
demonstrating OE, the percentage area of tumor cells exhibiting contiguous strong nuclear 
staining was estimated to the nearest 5%, and the average percentage of OE across all 
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scorable TMA cores from each case was calculated. Following review of discrepant cases 
regarding the TP53 status by established IHC criteria, we modified the threshold for OE: 
strong nuclear staining in contiguous areas of at least 5% of the tumor qualified as abnormal 
OE. Criteria for scoring other staining patterns (WT, CA, CY) remained unchanged. Two 
observers (MK, EK) independently scored TP53 IHC on 144 cases from the OTTA cohort using 
the refined criteria and agreement was assessed to evaluate interobserver reproducibility. A 
consensus was reached for discordant cases. During this we noted that the minimal 
threshold of 5% translated into ≥12 consecutive cells with strong nuclear staining. In the 
fallopian tube and the endometrium, a TP53 signature requiring at least 12 consecutive cells 
with abnormal-pattern TP53 staining has been shown to accurately predict TP53 mutations 
(16). Hence, ≥12 consecutive cells with strong nuclear staining was applied as an alternative 
threshold for minimal abnormal OE. 
 
Statistical analysis 
All statistical analyses were performed using R (v3.3.0). Fisher’s exact test was used for 
categorical data (stats::fisher.test) and the Wilcoxon rank sum test was used to compare 
two groups of continuous data (stats::wilcox.test). Interobserver concordance was tested 
using Cohen’s kappa for two raters with equal weights. Spearman correlation was used to 
compare concordance of two continuous variables (stats::cor.test, method = spearman).  
 
The primary endpoint for survival analysis was all cause mortality (overall survival). The 
secondary endpoint was progression free survival, defined by a clinical diagnosis of 
recurrence. Disease-specific survival was also considered when the cause of death was 
known. Overall survival was right censored at 10 years.  The OTTA cohort was left-truncated 
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to account for recruitment of prevalent cases. Survival analysis was performed using Cox 
proportional hazards regression model (survival::coxph). Included in the multivariate models 
were age (continuous variable) for MOC and MBOT, and for MOC also stage (stage I-II 
compared to stage III-IV) and grade (grades 1, 2 and 3 treated as categorical variables). In 
the analysis of the combined cohorts, cohort (OTTA and GAMuT) was included as a 
stratifying variable. Kaplan-Meier plots were used to visualize survival data using 
survminer::ggsurvplot. The assumptions of the Cox proportional hazards test were tested 
using survival::cox.zph on the multivariate models and visualized using ggcoxzph. No serious 





Concordance of TP53 IHC with TP53 mutation status 
In Part I of this study, we evaluated 113 cases (101 MOC; 12 MBOT) from the GAMuT cohort 
with both TP53 sequencing data and tissue stained for TP53 IHC. Using the established 
criteria from ovarian and endometrial carcinomas, abnormal versus normal TP53 IHC (Figure 
1A-D) showed concordance with TP53 mutation status for 82/113 (72.6%) cases (75.0% in 
MBOT and 72.5% in MOC). Twenty-eight out of 31 discordant cases were considered to be 
false negatives as they were scored as having normal TP53 IHC but mutations detected by 
sequencing. Only three cases were regarded as false positives with abnormal TP53 IHC but 
no mutation detected. The estimated allele frequencies of TP53 mutations were not 
statistically significantly different between concordant and discordant cases (median 0.57 
and 0.48, respectively; Wilcoxon rank sum test; p = 0.305), suggesting that discordance was 
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not commonly an effect of low tumor cellularity or clonal heterogeneity in TP53 mutation 
status. 
 
We then performed quality control analyses on discordant cases. Discordant cases on TMA 
were re-stained using full sections. When reviewing full sections, we observed a distinct 
pattern of OE staining in some cases, where the basal layer of cells demonstrated abnormal 
OE pattern staining with sparing of superficial areas (Figure 1E). A similar phenomenon has 
previously been described in squamous cell carcinomas and is referred to as “terminal 
differentiation” (10). Notably, terminal differentiation was not observed in cases showing 
the other two abnormal patterns: CA and CY. In addition, we observed intratumoral 
heterogeneity, where TP53 normal coexisted with abnormal TP53 IHC; this has previously 
been referred to as a “subclonal” pattern (15). Therefore, we repeated the interpretation 
with refined criteria to account for terminal differentiation and intratumoral heterogeneity. 
In cases with a missense mutation, the percentage of continuous tumor cell nuclei showing 
OE ranged from 5 to 100% (median 50%) (Figure 2A-D). We classified cases with a minimum 
of OE in 5% of tumor cell nuclei as abnormal TP53 IHC (Figure 2A). With the refined criteria, 
concordance improved to 91.7% in MBOT and 95.1% in MOC (overall 106/113 cases, 93.8%). 
Improvement in concordance was observed in cases with missense and splicing mutations, 
while concordance for non-mutated tumors and cases with truncating mutations remained 
the same since criteria for IHC patterns associated with truncating mutations were 
unchanged (Figure 2E). Using refined criteria, 77/113 (68.1%) cases demonstrated abnormal 




MBOT had a significantly lower median percentage of OE cells than MOC (35%, N=11 vs 
60%, N=69, respectively; Wilcoxon rank sum test; p=0.040) (Figure 2F). However, the allele 
frequency of MBOT TP53 mutations was not significantly different from MOC (median 0.44 
and 0.55 respectively; Wilcoxon rank sum test; p=0.38) (Figure 2G). Notably, there was no 
correlation between percentage of OE and allelic frequency (r=0.137; Spearman correlation; 
p=0.318, Supplementary Figure S2). This result suggests that MBOT cases with similar allelic 
frequencies of mutated cells but a lower OE distribution may be particularly prone to 
terminal differentiation. Indeed, in one case where we extracted DNA from both borderline 
and invasive components, the allele frequency of the mutated allele was similar (0.67 MBOT 
vs 0.46 MOC), whereas the percentage of overexpressing cells was higher in the invasive 
component (40% vs 100%). 
 
Following quality control and application of the refined threshold for abnormal-type OE, the 
number of discordant cases decreased from 31 to 7 (Table 2). All had their mutation status 
confirmed through repeat sequencing of TP53 using Sanger Sequencing, and IHC 
interpretation was re-reviewed and initial TMA IHC scores were confirmed on full tissue 
sections. 
 
Robustness of the IHC method 
Interobserver reproducibility for IHC scoring with the refined criteria by a second 
independent observer showed substantial agreement in an independent cohort from OTTA 
(k=0.80; N=144; Cohen’s kappa for two raters with equal weights). Review of discordant 
cases showed that disagreement most commonly occurred for cases with focal OE versus 
normal pattern (Supplementary Figure S3). We felt that the TP53 signature criteria of ≥12 
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consecutive cells with an OE TP53 staining pattern would be more easily applied compared 
to a 5% threshold and therefore utilized this as the minimal threshold for OE in the 
expanded cohort. 
 
Association of TP53 status with survival in MBOT and MOC 
Given the excellent concordance rates between TP53 IHC and TP53 mutation status, we 
considered IHC and sequencing equivalent and explored the association of TP53 status with 
survival using all available cases from the GAMuT and OTTA cohorts with IHC and/or 
sequencing data. The frequency of patterns of TP53 IHC observed in MBOT and MOC from 
both cohorts is summarized in Supplementary Table 2. The distribution of the percentages 
of abnormal OE in MBOT and MOC from both cohorts is shown in Supplementary Figure S4. 
There were 5 MBOT cases coded as stage III. Review of the pathology report of one case 
revealed that stage III was assigned clinically based on adhesion to bowel. However, there 
are no well documented cases of MBOT at stage III and we were not able to reconcile the 
discrepancy for the other 4 cases, therefore, the 5 “stage III” MBOT cases were excluded 
from the survival analysis. There were 32/165 (19.4%) TP53 abnormal MBOT cases. The age 
was not statistically different between TP53 abnormal (mean 51.9 years) and TP53 normal 
(mean 48.6 years) MBOT cases. TP53 abnormal MBOT had a worse progression-free 
(HR=4.8; 95%CI 1.4-17; likelihood ratio test; p=0.013), disease-specific (HR=4.5; 95%CI 1.1-
18; p=0.033), and overall survival (HR=4.5; 95%CI 1.5-14; p=0.0087). (Figure 3A, C, E). Five-
year progression-free survival for TP53 abnormal MBOT cases was 79.7%, and 95.9% for 
TP53 normal cases. Five-year overall survival for TP53 abnormal MBOT was 77.9%, and 
96.5% for TP53 normal cases. TP53 status was still a significant factor when age was taken 
into account in a multivariable analysis of progression-free (HR=5.7; 95%CI 1.6-20.4; 
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p=0.007) and overall survival (HR=4.6; 95%CI 1.5-14.3; p=0.009). We did not have sufficient 
power to establish the prognostic significance of TP53 separately in either the GAMuT or 
OTTA cohort due to low numbers of events, although similar trends were observed 
(Supplementary Figure S5). No significant differences were observed between the HRs of 
the two cohorts. 
 
Within MOC, 61.1% (259/424) harbored a TP53 mutation. Univariable associations of TP53 
status with clinicopathological parameters are shown in Table 3. TP53 mutation was 
previously found not to be significantly associated with MOC survival (5), and this remained 
the case in the combined GAMuT and OTTA cohorts (Figure 3B,D,F). However, significant 
differences were observed in the HRs between the cohorts, suggesting heterogeneity in the 
outcomes for MOC between the studies. In the GAMuT cohort TP53 abnormal cases showed 
worse progression-free survival (HR=2.99; 95%CI 1.3-6.8; p=0.008), overall survival (HR=2.5; 
95% CI 1.2-5.4; p=0.02) and disease-specific survival (HR=3.0; 95% CI 1.3-7.2; p=0.01) 
compared to TP53 normal. However, in the OTTA cohort, TP53 was not significantly 








This study is the first to validate the use of TP53 IHC as a surrogate marker of TP53 mutation 
status in ovarian mucinous tumors. A high level of accuracy can be reached if the 
interpretation criteria are refined to account for terminal differentiation and intratumoral 
heterogeneity. The accuracy of 93.8% is close to accuracies of 95-97% previously reported in 
ovarian high-grade serous and endometrioid carcinomas as well as endometrial carcinomas 
(8, 9). With IHC and sequencing being equivalent assays, we then provide strong evidence 
against an association of TP53 mutation status with survival in MOC (5). However, we show 
that TP53 mutation is a prognostic risk factor in MBOT, which could inform clinical 
management. 
 
In contrast to other ovarian carcinoma histotypes, ovarian mucinous tumors show terminal 
differentiation and a high degree of intratumoral heterogeneity. The phenomenon of 
terminal differentiation has been well-documented in squamous cell carcinomas (10). In 
many squamous cell carcinomas, abnormal TP53 expression is seen in the actively 
proliferating “basal” and sometimes also in “parabasal” zones. It is absent in the more 
differentiated or “superficial” zones most likely due to downregulation of transcription, 
given that RNA in situ hybridization has failed to detect TP53 mRNA in these zones (10). 
Although similar studies have not been done in ovarian mucinous tumors, abrupt loss of 
protein expression in the luminal aspects of papillary proliferations may suggest an 
analogous mechanism. Therefore, luminal aspects should be disregarded when interpreting 
TP53 IHC in ovarian mucinous tumors. Further exploration of terminal differentiation in 
tumors arising in the ovary as well as mucinous tumors from other organ systems, such as 
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the gastrointestinal tract, may be useful to delineate the underlying mechanism and 
understand the possible significance of this phenomenon. 
 
A high degree of intratumoral heterogeneity poses another challenge in the interpretation 
of TP53 IHC in ovarian mucinous tumors. These tumors are large (mean size 20 cm) and 
often show an admixture of benign and malignant components. This can result in subclonal 
TP53 expression with different areas showing normal or abnormal patterns. We found a low 
threshold of 5% consecutively strongly staining cells was predictive of a TP53 mutation but 
noticed that the 5% rule led to minor differences in interobserver reproducibility. On 
review, we concluded that this translates into at least 12 consecutive strongly staining 
tumor cells, similar to the TP53 signature described in the fallopian tube (16). With such a 
low threshold, it is important not to overinterpret small foci of high but normal staining 
pattern, which still show variable staining intensity, as abnormal. In contrast, TP53 
mutations are ubiquitously found and hence considered a required early event in tubo-
ovarian high-grade serous carcinoma (17). Therefore, these tumors frequently exhibit 
abnormal TP53 IHC patterns and TP53 mutations uniformly, improving the sensitivity of 
assays utilizing limited tissue samples. 
 
After quality control, a few cases with discrepant TP53 status based on IHC and sequencing 
remained. Possible explanations for “false negative” cases include 1) false negative IHC in 
cases with likely pathogenic TP53 mutations, 2) late truncating mutations expressing non-
functional truncating proteins, and 3) variants of uncertain significance, in which IHC may 
aid in classification (14). The 4 “false positive” cases may represent false positive IHC, but a 
false negative sequencing result due to large deletions at least in one case with complete 
16 
 
absence cannot be ruled out. Furthermore, low frequency variants may not have been 
detected on sequencing thus don’t match the TP53 abnormal IHC pattern identified on 
representative tissue sections. This explanation is plausible since the most representative 
FFPE block was analyzed by IHC, whereas for the three exome sequenced cases, the frozen 
tissue fragment used for DNA extraction was opportunistically sampled and may contain 
non-tumor or benign cells in addition to tumor cells, reducing the sensitivity of mutation 
detection. The lower coverage of the exome analysis (~60X) compared to targeted 
sequencing could make detection of low-frequency variants more challenging. Additionally, 
we cannot entirely exclude sample mix-up prior to DNA extraction as newly extracted DNA 
samples were not available due to limited material. Finally, TP53 expression is not solely 
dependent on the mutation status of TP53, but also relies on other factors such as MDM2 
and chaperone activities, gene copy number, and mRNA levels (10), which may have been 
altered in discordant cases. 
 
Identification of TP53-mutated MBOT through the use of TP53 IHC can highlight cases with 
increased risk of progression to carcinoma or concurrent unsampled invasive carcinoma 
elsewhere in the tumor mass. The latter finding has been previously made in an early study 
showing that p53 overexpression was associated with microinvasion and invasion (6). MBOT 
often requires extensive tumor sampling to search for invasion. For our study, it was not 
feasible to track sampling protocols for every case given the multi-institutional nature, and 
that case accrual spanned over several decades. Following the 2003 Bethesda Borderline 
Ovarian Tumor Workshop, a standard sampling protocol of two sections for each cm of the 
tumor's largest dimension was implemented in centers contributing to this study (18). 
However, an unknown proportion of MBOT cases accrued before or around 2003 might not 
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have been sampled according to this standard. Therefore, it is possible that some TP53 
abnormal MBOT cases may have had unsampled invasive foci elsewhere. While abnormal 
TP53 could potentially flag these cases, normal TP53 status, on the other hand, could be 
used to de-escalate treatment in certain clinical scenarios such as ruptured MBOT. This 
leads to an important question: which tumors should have TP53 IHC testing? From our 
undocumented observations, we believe abnormal TP53 IHC occurs in areas with high-grade 
nuclear atypia that raises a morphological suspicion of intraepithelial carcinoma. Yet the 
abnormal TP53 staining pattern often extends beyond the area thought to be intraepithelial 
carcinoma based on morphology. Future studies are required to determine the relationship 
of TP53 mutation and intraepithelial carcinoma in MBOT since the current consensus is that 
MBOT with intraepithelial carcinoma still has a favorable outcome with >95% survival (19).  
A threshold for ordering TP53 IHC in ovarian mucinous tumors should be established.  
 
We confirm that TP53 mutations are implicated in later progression of MBOT to MOC 
because TP53 mutations increase in frequency from MBOT 19.4% vs MOC 61.2% (5). TP53 is 
not associated with prognosis in MOC, at least when analyzed without the context of other 
key oncogenic events such as KRAS, CDKN2A and ERBB2. 
 
In conclusion, TP53 IHC is an accurate proxy for TP53 mutation status with refined 
interpretation criteria accounting for terminal differentiation in MBOT and MOC with good 
interobserver reproducibility. TP53 mutation status inferred by IHC may be a useful 
biomarker to identify MBOT with a higher risk of mortality, suggesting a closer follow-up of 
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Figure 1. TP53 immunohistochemistry staining patterns. A. Normal pattern with 
heterogeneous nuclear staining in variable distribution. B. Abnormal overexpression (OE) 
with virtually all viable tumor cell nuclei showing strong nuclear staining. C. Abnormal 
complete absence with no nuclear staining of tumor cells but normal control staining in non-
tumor stromal or immune cells. D. Abnormal cytoplasmic staining with unequivocal 
cytoplasmic staining and variable nuclear staining. E. Mucinous borderline tumor with 
intratumoral heterogeneity or subclonal TP53 abnormal pattern. Inset: both normal (upper) 
and abnormal OE patterns (lower) are seen within the same tumor. Abnormal OE is seen in 
an area of mucinous intraepithelial carcinoma. In addition, abnormal OE area displays 
terminal differentiation with the basal layer of cells demonstrating abnormal OE pattern 
staining with sparing of superficial areas. 
 
Figure 2. TP53 immunohistochemistry and TP53 mutations by sequencing in ovarian 
mucinous tumors. Ovarian mucinous tumors with variable percentages of TP53 
overexpression: A. 5% overexpression or > 12 consecutive strongly staining cells. B. 50% 
overexpression. C. 70% overexpression. D. 100% overexpression. E. Concordance between 
mutation status by sequencing and immunohistochemistry improved with application of 
refined (minimum 5% abnormal OE pattern) instead of established criteria, with 
improvements observed in cases with splicing and missense mutations. F. The percentage of 
tumor cells overexpressing TP53 in mucinous borderline tumors (MBOT) and carcinomas 
(MOC) (median 35% and N=11 in MBOT; median 60% and N=69 in MOC; p=0.040). G. TP53 




Figure 3. Kaplan-Meier survival plots of ovarian mucinous borderline tumors (MBOT) and 
mucinous carcinomas (MOC) stratified by TP53 status using mutation and 
immunohistochemistry data. A, C, E. Progression-free (PFS; A), overall (OS; C), and disease-
specific (DSS; E) survival in patients with MBOT. B, D, F. Progression-free (B), overall (D), and 





Table 1. Concordance of TP53 expression by IHC with TP53 mutation status in mucinous 
borderline tumors and mucinous carcinomas from the Genomic Analysis of Mucinous 
Tumors (GAMuT) cohort.  
 TP53 mutation type  
TP53 IHC Missense Inframe 
indel 
Truncating Splicing NMD Total 
Abnormal OE 54 3 0 2 3 62 
Abnormal CA 0 0 12 2 1 15 
Abnormal CY 0 0 0 0 0 0 
Normal 2 0 1 0 33 36 
Total 56 3 13 4 37 113 
OE = overexpression. CA = complete absence. CY = cytoplasmic. NMD = no mutation detected.   
Table 2. Mucinous borderline tumor (MBOT) and mucinous carcinoma (MOC) cases from 
the Genomic Analysis of Mucinous Tumors (GAMuT) cohort with discrepancies between 
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AF = allele frequency. TMA = tissue microarray. IARC = International Agency for Research on 
Cancer. VUS = variant of uncertain significance. NMD = no mutation detected. NA = not 
applicable. OE = overexpression. CA = complete absence. 
Table 3.  Univariable association of TP53 status in MOC with clinico-pathological 
parameters in a survival cohort combining the Genomic Analysis of Mucinous Tumors 
(GAMuT) and the Ovarian Tumor Tissue Analysis (OTTA) consortium. 
 TP53 normal TP53 abnormal p-value 
MOC (N) 165 259  
Age, mean (SE) 51.4 +/- 8.6 52.1 +/- 8.6 p=0.25, t =-1.151 
Stage    
I-II 136 (85.0%) 222 (89.1%) p=0.222 
III-IV 24 (15.0%) 27 (10.8%)  
Unknown 5 10  
Grade    
1 66 (44.9%) 84 (36.8%) p=0.152 
2 66 (44.9%) 107 (46.9%)  
3 15 (10.2%) 37 (16.2%)  
Unknown 18 31  
1. Welch t-test, 2 sided 
2. Fisher’s exact test, 2-sided 
MOC = mucinous ovarian carcinoma. SD = standard deviation 
